Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer. Mr. Okazaki joined Assembly Bio in 2020 as chief legal and business officer responsible for leading and executing strategic collaborations and transactions. Since joining Assembly Bio in 2017, Mr. Samar has led the company's financial and business operations, serving most recently as senior vice president of finance and business operations.

Assembly Bio Announces Key Promotions to Leadership Team

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experience Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experience

Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for presentation during the International Liver Congress™ 2021, the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place virtually June 23-26, 2021. During the meeting, data from Assembly Bio's three core inhibitor programs, vebicorvir (VBR), ABI-H2158 (2158) and ABI-H3733 (3733), will be featured in an oral presentation and two poster presentations.

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates

Earnings Preview: Assembly Biosciences (ASMB) Q1 Earnings Expected to Decline

Lumos Pharma

UTStarcom Holdings

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reassessed the share prices to near or above the liquidation value.

3 Net Current Asset Value Stocks

Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript

Arbutus Biopharma

Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for chronic HBV infection. The companies announced a clinical collaboration agreement in August last year.

Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection

Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B therapies. The CST study was supposed to be conducted with BeiGene Ltd (NASDAQ: BGNE), which licensed the rights to VBR in China.

Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -23.33% and -72.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates

- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - Extends cash runway into 2023 - Company to host conference call today at 5:00 p.m. ET/2:00 p.m. PT

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events:

Assembly Bio Announces Upcoming Investor Events

Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio

Assembly Biosciences to Wind-Down Microbiome Program

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing. Dr. White brings over 20 years of experience overseeing the complexities of the chemistry manufacturing and controls process.

Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals' innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with viral nucleic acid including cccDNA transcription, providing a strong complement to Assembly Bio's current portfolio.

Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators

- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV preg e n o mic ( pg ) RNA as a key biomarker , as well as highlight Assembly Bio's core inhibitor clinical pipeline -

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™

The clinical-stage biotech had a big pipeline setback.

Why Assembly Biosciences Stock Crashed Today

Assembly Biosciences (ASMB) news for Friday includes clinical trial information from its third quarter of 2020 dropping ASMB stock. The post Assembly Biosciences News: Why ASMB Stock Is Plunging 68% Today appeared first on InvestorPlace.

Assembly Biosciences News: Why ASMB Stock Is Plunging 68% Today

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 88.46% and 437.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates

- HBV field's first c ore i nhibitor combination study to assess off-treatment response has not achieve d a meaningful rate of sustained virologic response -  - Vebicorvir Phase 3 registrational program remain s on track to i nitiate in H1 2021 for c hronic s uppressive t herapy - - Assembly Bio to host conference call today at 5:00 p . m . ET -

Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

Will Assembly Biosciences (ASMB) Report Negative Q3 Earnings? What You Should Know

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors. Ms. Consylman will also serve as a member of Assembly's Audit Committee.

Assembly Biosciences Appoints Gina Consylman to Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV.

News for Assembly Biosciences Stock (ASMB)